ANGLE plc provided earnings guidance for the year 2023. The Company expects revenue recognised for 2023 will be c. £2.2 million, which is an increase of 120% over revenue achieved in 2022 but below current market consensus of c. £3.0 million. New sales secured in 2023 are expected to be c. £3.3 million however revenue recognition for some of these sales will fall into the 2024 financial year.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
20.7 GBX | -1.43% | -2.59% | +76.17% |
03/05 | Angle shares up on assay development deal with AstraZeneca | AN |
03/05 | Angle shares up on assay development deal with AstraZenaca | AN |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+76.17% | 68.66M | |
-42.86% | 2.82B | |
+20.51% | 1.91B | |
-1.13% | 1.65B | |
+26.40% | 1.25B | |
-14.07% | 988M | |
-20.60% | 910M | |
+0.81% | 786M | |
-24.34% | 634M | |
+10.38% | 507M |
- Stock Market
- Equities
- AGL Stock
- News ANGLE plc
- ANGLE plc Provides Earnings Guidance for the Year 2023